NO20030153L - Blandinger som inneholder terapeutisk aktive komponenter som har foröket löselighet - Google Patents

Blandinger som inneholder terapeutisk aktive komponenter som har foröket löselighet

Info

Publication number
NO20030153L
NO20030153L NO20030153A NO20030153A NO20030153L NO 20030153 L NO20030153 L NO 20030153L NO 20030153 A NO20030153 A NO 20030153A NO 20030153 A NO20030153 A NO 20030153A NO 20030153 L NO20030153 L NO 20030153L
Authority
NO
Norway
Prior art keywords
active components
therapeutically active
mixtures containing
increased solubility
containing therapeutically
Prior art date
Application number
NO20030153A
Other languages
English (en)
Other versions
NO20030153D0 (no
NO331816B1 (no
Inventor
Orest Olejnik
Edward D S Kerslake
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22814167&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20030153(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NO20030153D0 publication Critical patent/NO20030153D0/no
Publication of NO20030153L publication Critical patent/NO20030153L/no
Publication of NO331816B1 publication Critical patent/NO331816B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20030153A 2000-07-14 2003-01-13 Blandinger som inneholder terapeutisk aktive komponenter som har foroket loselighet NO331816B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21820600P 2000-07-14 2000-07-14
PCT/US2001/021551 WO2002005822A2 (en) 2000-07-14 2001-07-09 Compositions containing therapeutically active components having enhanced solubility

Publications (3)

Publication Number Publication Date
NO20030153D0 NO20030153D0 (no) 2003-01-13
NO20030153L true NO20030153L (no) 2003-01-13
NO331816B1 NO331816B1 (no) 2012-04-10

Family

ID=22814167

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030153A NO331816B1 (no) 2000-07-14 2003-01-13 Blandinger som inneholder terapeutisk aktive komponenter som har foroket loselighet

Country Status (23)

Country Link
US (2) US6562873B2 (no)
EP (2) EP1301210A2 (no)
JP (1) JP2004503593A (no)
KR (1) KR20030023700A (no)
CN (1) CN1441679A (no)
AR (1) AR035039A1 (no)
AU (2) AU7326801A (no)
BR (1) BR0112461A (no)
CA (1) CA2416169C (no)
CY (1) CY1113391T1 (no)
DK (1) DK2153819T3 (no)
ES (1) ES2392636T3 (no)
HU (1) HU230383B1 (no)
IL (2) IL153322A0 (no)
MX (1) MXPA02012206A (no)
NO (1) NO331816B1 (no)
NZ (1) NZ522610A (no)
PL (1) PL361027A1 (no)
PT (1) PT2153819E (no)
RU (1) RU2291685C2 (no)
TW (1) TWI287992B (no)
WO (1) WO2002005822A2 (no)
ZA (1) ZA200209877B (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1301210A2 (en) * 2000-07-14 2003-04-16 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
NZ521185A (en) * 2000-07-14 2005-02-25 Allergan Inc Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050282774A1 (en) * 2000-10-31 2005-12-22 Eek Bjorn C Method and pharmaceutical to treat spinal discs
US20030114460A1 (en) * 2001-12-14 2003-06-19 Allergan Sales, Inc. Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US6982079B2 (en) * 2002-04-26 2006-01-03 Allergan, Inc. Compositions for treating hyperemia
WO2004010894A2 (en) 2002-07-30 2004-02-05 Omeros Corporation Ophthalmologic irrigation solutions and method
US20040137079A1 (en) * 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US6933289B2 (en) * 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7022740B2 (en) * 2004-04-29 2006-04-04 Leonard Mackles Lubricious ophthalmic solutions
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
RU2008122978A (ru) 2005-11-09 2009-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы, композиции и наборы для лечения медицинских состояний
US20070238732A1 (en) * 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
CN102026665A (zh) * 2008-05-19 2011-04-20 爱尔康研究有限公司 含有羧基乙烯基聚合物和聚维酮聚合物的药物组合物
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
DK2320911T3 (da) * 2008-08-01 2014-11-03 Eye Therapies Llc Vasokonstriktionspræparater og fremgangsmåder til anvendelse deraf
US20110244058A1 (en) * 2008-08-01 2011-10-06 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8409606B2 (en) 2009-02-12 2013-04-02 Incept, Llc Drug delivery through hydrogel plugs
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US20110152271A1 (en) * 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
ES2634551T3 (es) 2010-04-03 2017-09-28 Praful Doshi Métodos para revestir una lente de contacto
WO2011127139A2 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservative compositions for ophthalmic formulations
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
WO2012041910A1 (de) 2010-10-01 2012-04-05 Elektra Management S.R.O. Lösung von guanidinium-verbindungen, verfahren unter einsatz dieser lösung sowie deren verwendung
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
HUE049489T2 (hu) 2011-12-07 2020-09-28 Allergan Inc Hatékony lipidbevitel emberi könnyfilmbe sóérzékeny emulziós rendszer alkalmazásával
MX354990B (es) * 2012-01-20 2018-03-28 Aratana Therapeutics Nv Composicion de gotas para los ojos.
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
EP3086776B1 (en) 2013-12-24 2020-06-17 Sentiss Pharma Private Limited Topical brimonidine tartrate ophthalmic solution
CA2967413C (en) 2014-11-25 2023-08-15 Allergan, Inc. Ophthalmic compositions containing omega-3 oils stabilized by antioxidants
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
AU2016233125A1 (en) * 2015-03-19 2017-09-14 Allergan, Inc. Fixed dose combination of bromonidine and timolol
CA3033507A1 (en) 2016-08-12 2018-02-15 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
RS62817B1 (sr) * 2017-05-11 2022-02-28 Vyluma Inc Farmaceutske kompozicije atropina
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
EP4142689A1 (en) 2020-04-29 2023-03-08 Sentiss Pharma Private Limited Ophthalmic compositions comprising a combination of brinzolamide and brimonidine
GR1010024B (el) * 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
JP2021183606A (ja) * 2020-05-20 2021-12-02 千寿製薬株式会社 ブリモニジンを含有する液体製剤

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL286080A (no) * 1961-11-30
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4089969A (en) 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
JPS542338A (en) * 1977-04-22 1979-01-09 Sandoz Ag Pharmaceutical composition
US4474787A (en) 1977-05-04 1984-10-02 Fisons Limited 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4530920A (en) 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4806556A (en) 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5352796A (en) 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
GB9017353D0 (en) 1990-08-08 1990-09-19 Merck Sharp & Dohme Chemical process
ATE185697T1 (de) 1992-04-21 1999-11-15 Schepens Eye Res Inst Androgentherapie am auge beim sjögrensyndrom
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
AU6124494A (en) 1993-01-28 1994-08-15 University Of Iowa Research Foundation, The Ophthalmic uses of signa agonists
WO1995010280A1 (en) 1993-10-13 1995-04-20 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5994110A (en) 1995-02-10 1999-11-30 Mosbach; Klaus Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
ZA965837B (en) 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
US5952345A (en) 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
EP0834308A1 (en) 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
JP2001522358A (ja) 1997-04-18 2001-11-13 アボツト・ラボラトリーズ 高純度６，７−ジクロロ−５−ニトロ−２，３−ジヒドロキノキサリン−２，３−ジオンの調製方法
AU2870899A (en) 1998-02-26 1999-09-15 Abbott Laboratories Oral formulation for hydrophilic drugs
DK1069913T3 (da) 1998-04-07 2003-11-17 Alcon Mfg Ltd Gelatinering af ophthalmiske sammensætninger indeholdende xanthangummi
WO2000012137A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
DE69923987T2 (de) * 1998-10-08 2006-11-02 Karagoezian, Hampar L., San Juan Capistrano Synergistische antimikrobielle, dermatologische und ophtahalmologische zubereitung, die ein chlorit und wasserstoffperoxid enthalten
US6514504B1 (en) * 1999-08-18 2003-02-04 The Procter & Gamble Company Discontinuous films from skin care compositions
EP1301210A2 (en) * 2000-07-14 2003-04-16 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
NZ521185A (en) * 2000-07-14 2005-02-25 Allergan Inc Compositions containing alpha-2-adrenergic agonist components

Also Published As

Publication number Publication date
CY1113391T1 (el) 2016-06-22
ZA200209877B (en) 2003-09-29
CA2416169A1 (en) 2002-01-24
HU230383B1 (hu) 2016-03-29
EP2153819A2 (en) 2010-02-17
NO20030153D0 (no) 2003-01-13
US20020071874A1 (en) 2002-06-13
DK2153819T3 (da) 2012-12-03
NO331816B1 (no) 2012-04-10
CN1441679A (zh) 2003-09-10
JP2004503593A (ja) 2004-02-05
PT2153819E (pt) 2012-11-14
WO2002005822A2 (en) 2002-01-24
AU2001273268B2 (en) 2005-08-25
US6562873B2 (en) 2003-05-13
IL153322A (en) 2011-01-31
NZ522610A (en) 2004-11-26
ES2392636T3 (es) 2012-12-12
HUP0301405A3 (en) 2006-02-28
CA2416169C (en) 2008-09-23
PL361027A1 (en) 2004-09-20
MXPA02012206A (es) 2003-06-04
HUP0301405A2 (hu) 2003-08-28
EP2153819A3 (en) 2010-05-12
US20030153530A1 (en) 2003-08-14
EP1301210A2 (en) 2003-04-16
EP2153819B1 (en) 2012-09-05
TWI287992B (en) 2007-10-11
IL153322A0 (en) 2003-07-06
RU2291685C2 (ru) 2007-01-20
AR035039A1 (es) 2004-04-14
KR20030023700A (ko) 2003-03-19
AU7326801A (en) 2002-01-30
BR0112461A (pt) 2003-07-22
WO2002005822A3 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
NO20030153L (no) Blandinger som inneholder terapeutisk aktive komponenter som har foröket löselighet
NO20032101D0 (no) Apoliprotein analoger
ITMI20011489A0 (it) Miscele stabilizzanti
NO20026195D0 (no) Substituerte-triazolopyrimidiner som anticancer midler
DK1317177T3 (da) Desinficerende formuleringer
AR028291A1 (es) Formulaciones oftalmicas
NO20026037L (no) Sötvareprodukt som inneholder aktive bestanddeler
NO20033969L (no) Triazolpyridiner som anti-inflammatoriske midler
NO20014759L (no) C(7)-estersubstituerte taxaner som antitumormidler
NO20032613D0 (no) Farmasöytisk sammensetning som har en forbedret vannopplöselighet
DE60110855D1 (de) Wellenlängenstabilisierte Laseranordnung
NO20022888L (no) Lipopeptider som antibakterielle midler
DE60135103D1 (de) Endoskopische stabilisierungsvorrichtung
NO20022887D0 (no) Lipopeptider som antibakterielle midler
MXPA03001425A (es) Compuestos farmaceuticos.
DE50213466D1 (de) Fungizide wirkstoffkombinationen
DK1429607T3 (da) Delta-1-pyrroliner som pesticider
NO20032614L (no) Farmasöytisk sammensetning som har forbedret absorberbarhet
NL1018186A1 (nl) Stabilisatormengsels.
ATE270043T1 (de) Fungizide wirkstoffkombinationen
NL1018187A1 (nl) Stabilisatormengsels.
DK1263734T3 (da) 3-thiomethylpyrazoler som pesticider
NL1018188A1 (nl) Stabilisatormengsels.
NO20013441D0 (no) Sammensetninger som har forbedret stabilitet
NO20012965D0 (no) Sulfonyloksazolaminer som terapeutisk aktive forbindelser

Legal Events

Date Code Title Description
MK1K Patent expired